<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-10-27" updated="2019-12-02">
  <drugbank-id primary="true">DB09263</drugbank-id>
  <name>Patiromer</name>
  <description>Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patiromer is equivalent to a nominal amount of 2 grams of patiromer sorbitex calcium. The chemical name for patiromer sorbitex calcium is cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene, combination with D-glucitol. Patiromer sorbitex calcium is an amorphous, free-flowing powder that is composed of individual spherical beads.</description>
  <cas-number>1260643-52-4</cas-number>
  <unii>1FQ2RY5YHH</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7872</ref-id>
        <pubmed-id>21208974</pubmed-id>
        <citation>Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ: Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011 Apr;32(7):820-8. doi: 10.1093/eurheartj/ehq502. Epub 2011 Jan 5.</citation>
      </article>
      <article>
        <ref-id>A7873</ref-id>
        <pubmed-id>26456884</pubmed-id>
        <citation>Montaperto AG, Gandhi MA, Gashlin LZ, Symoniak MR: Patiromer: a clinical review. Curr Med Res Opin. 2016;32(1):155-64. doi: 10.1185/03007995.2015.1106935. Epub 2015 Nov 19.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of hyperkalemia.</indication>
  <pharmacodynamics>In clinical studies, patiromer decreased systemic exposure of some coadministered oral medications. Binding of patiromer to other oral medications could cause decreased gastrointestinal absorption and loss of efficacy when taken close to the time patiromer is administered. Administer oral medications at least 3 hours before or 3 hours after patiromer.</pharmacodynamics>
  <mechanism-of-action>Patiromer is a non-absorbed, cation exchange polymer that contains a calcium-sorbitol counterion. It increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption>In radiolabeled studies in cats and dogs, patiromer was not systemically absorbed.</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination>Excretion in feces. </route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001352</drugbank-id>
      <name>Patiromer sorbitex calcium</name>
      <unii>0LB9J2797D</unii>
      <cas-number/>
      <inchikey/>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="usan">Patiromer</synonym>
    <synonym language="english" coder="">Patiromer FOS</synonym>
  </synonyms>
  <products>
    <product>
      <name>Veltassa</name>
      <labeller>Vifor Fresenius Medical Care Renal Pharma Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02481375</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>25.2 g</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Veltassa</name>
      <labeller>Relypsa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53436-168</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>16.8 g/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA205739</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Veltassa</name>
      <labeller>Relypsa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53436-252</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>25.2 g/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA205739</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Veltassa</name>
      <labeller>Relypsa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>53436-084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>8.4 g/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA205739</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Veltassa</name>
      <labeller>Vifor Fresenius Medical Care Renal Pharma Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02481359</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>8.4 g</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Veltassa</name>
      <labeller>Vifor Fresenius Medical Care Renal Pharma Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02481367</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>16.8 g</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Veltassa</name>
      <ingredients>Patiromer</ingredients>
    </mixture>
    <mixture>
      <name>Veltassa</name>
      <ingredients>Patiromer</ingredients>
    </mixture>
    <mixture>
      <name>Veltassa</name>
      <ingredients>Patiromer</ingredients>
    </mixture>
    <mixture>
      <name>Veltassa</name>
      <ingredients>Patiromer</ingredients>
    </mixture>
    <mixture>
      <name>Veltassa</name>
      <ingredients>Patiromer</ingredients>
    </mixture>
    <mixture>
      <name>Veltassa</name>
      <ingredients>Patiromer</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Macromolecular Substances</category>
      <mesh-id>D046911</mesh-id>
    </category>
    <category>
      <category>Potassium Binder</category>
      <mesh-id/>
    </category>
    <category>
      <category>Potassium Ion Binding Activity</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>16.8 g/1</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>16.8 g</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>25.2 g/1</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>25.2 g</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>8.4 g/1</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>8.4 g</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB09263.pdf?1445960725</fda-label>
  <patents>
    <patent>
      <number>8475780</number>
      <country>United States</country>
      <approved>2013-07-02</approved>
      <expires>2024-03-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8216560</number>
      <country>United States</country>
      <approved>2012-07-10</approved>
      <expires>2027-03-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8889115</number>
      <country>United States</country>
      <approved>2014-11-18</approved>
      <expires>2024-03-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8337824</number>
      <country>United States</country>
      <approved>2012-12-25</approved>
      <expires>2030-05-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7556799</number>
      <country>United States</country>
      <approved>2009-07-07</approved>
      <expires>2025-02-27</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8778324</number>
      <country>United States</country>
      <approved>2014-07-15</approved>
      <expires>2024-03-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8287847</number>
      <country>United States</country>
      <approved>2012-10-16</approved>
      <expires>2024-03-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8282913</number>
      <country>United States</country>
      <approved>2012-10-09</approved>
      <expires>2026-03-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8147873</number>
      <country>United States</country>
      <approved>2012-04-03</approved>
      <expires>2026-03-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9492476</number>
      <country>United States</country>
      <approved>2016-11-15</approved>
      <expires>2033-10-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9925212</number>
      <country>United States</country>
      <approved>2018-03-27</approved>
      <expires>2033-10-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>Patiromer can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>Patiromer can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>Patiromer can cause a decrease in the absorption of Metformin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>22995</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910426</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D10148</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Patiromer</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2107875</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004816</id>
      <name>Potassium</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18387</ref-id>
            <pubmed-id>21383002</pubmed-id>
            <citation>van der Meer P, van Veldhuisen DJ: To bind or not to bind: potassium-lowering drugs in heart failure. Eur Heart J. 2011 Apr;32(7):791-2. doi: 10.1093/eurheartj/ehr058. Epub 2011 Mar 7.</citation>
          </article>
          <article>
            <ref-id>A7872</ref-id>
            <pubmed-id>21208974</pubmed-id>
            <citation>Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ: Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011 Apr;32(7):820-8. doi: 10.1093/eurheartj/ehq502. Epub 2011 Jan 5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>